Get all your news in one place.

100's of premium titles.
One app.

Get all your news in one place.

100's of premium titles. One news app.

The Latest Breaking News from Needham

Analysts Hailed CarMax's Q1 Performance While Highlighting Concerns

Analysts lauded CarMax Inc's (NYSE:KMX) Q1 beat while also pointing out the macro concerns. RBC Capital analyst Steven Shemesh maintained CarMax with an Outperform and raised the price target from $104 to $108 in a note titled, "F1Q'23 Follow-Up – Navigating Volatility Well." KMX's results were broadly in line with expectations, Shemesh noted. He expected the inflationary…

Benzinga's Top Ratings Upgrades, Downgrades For June 27, 2022

Benzinga's Top Ratings Upgrades, Downgrades For June 27, 2022

Read Why Needham Is Bullish On This Pet Care Retailer

Read Why Needham Is Bullish On This Pet Care Retailer

Needham analyst Anna Andreeva upgraded Chewy Inc (NYSE:CHWY) to Buy from Hold with a price target of $55, implying a 44% upside. The analyst said the company had exceeded expectations in Q1 FY22 after missing consensus EBITDA for four quarters. Andreeva thinks the positive momentum continued in Q2 as the pet category was inelastic, with price increases sticking,…

From analysis to the latest developments in health,
read the most diverse news in one place.

inkl

Etsy Shares Drop As Needham Downgrades Stock Citing Near-Term Risks

Needham analyst Anna Andreeva downgraded Etsy, Inc (NASDAQ:ETSY) from Buy to Hold. While shares have lagged and some near-term volatility is arguably in the stock, she views the discretionary nature of the ETSY model as increasingly at risk in the near term. While visibility is low, she thought that consensus GMS and Sales estimates…

Needham Is Bullish On This Botox Equivalent Aesthetics Company

Needham initiated coverage on Evolus Inc (NASDAQ:EOLS) with a price target of $18.00 (43% upside) and a Buy rating. Evolus is a pure-play aesthetics company focused on growing the presence of Jeuveau, its new neurotoxin product, in the approximately $3 billion global wrinkle treatment market. Jeuveau is a prescription medicine injected into muscles to improve…

Ad Industry's Biggest Conference Returns With New Winner: Find Out Who

The advertising industry's biggest conference has returned with a new winner Amazon.com, Inc (NASDAQ: AMZN), after a two-year break, Bloomberg reports. Amazon occupied a portion of the beachfront at the annual Cannes Lions show with the "Amazon Port," its most extensive showcasing at the conference yet reflecting its growing significance. Tech companies like Alphabet Inc (NASDAQ:GOOG)…

Needham Expresses Bullishness On US Ride-Share Industry; Uber Remains On Conviction List

Needham analyst Bernie Mcternan forecasted a 24% 3-year CAGR for U.S. ride-share bookings through 2025, down from the 45% CAGR in the three years heading into the pandemic. Company data, industry reports, and a proprietary survey of 500+ U.S. consumers supported the forecast.

inkl

Read news from The Economist, FT, and more,
with one subscription

Here's Why Needham Predicts Taboola Shares To Double

Here's Why Needham Predicts Taboola Shares To Double

Needham analyst Laura Martin reiterated Buy on Taboola.com Ltd (NASDAQ:TBLA) with a price target of $5 (95.3% upside). Martin cited the eMarketer report that advertising revenue on the Open Internet (excluding Walled Gardens like Amazon.com Inc (NASDAQ: AMZN), Meta Platforms Inc's (NASDAQ:META) Facebook, Alphabet Inc (NASDAQ:GOOG) (NASDAQ:GOOGL) Google, YouTube, Snap Inc (NYSE:SNAP), and Roku, Inc (NASDAQ:ROKU)) is about $40 billion in the U.S. and about…

Needham Sees Above 72% Upside In This Conviction List Stock; Here's Why

Needham Sees Above 72% Upside In This Conviction List Stock; Here's Why

Needham analyst Chris Pierce anticipated CarGurus, Inc (NASDAQ: CARG) leveraging its industry-leading traffic metrics over the long term to create a compelling end-to-end digital solution for independent brick and mortar car dealerships.

Needham Lists Four Trends Aced By This Netflix Spin Off

Needham Lists Four Trends Aced By This Netflix Spin Off

Needham analyst Laura Martin saw Roku, Inc (NASDAQ: ROKU) as a pure-play way to invest in the growth of the U.S. over-the-top (OTT) and connected-TV (CTV) ecosystems.

Needham Remained Bullish On KLA Corp Post Investor Day - Read Why

Needham Remained Bullish On KLA Corp Post Investor Day - Read Why

Needham hailed KLA Corp's (NASDAQ: KLAC) 2022 Investor Day in NYC in a note titled "Investor Day Reveals New 2026 Model Targeting Revenue of $14bn and EPS of $38."

Needham Considers It Futile For Meta To Compete With TikTok, YouTube, Amazon, Google

Needham Considers It Futile For Meta To Compete With TikTok, YouTube, Amazon, Google

Needham's Laura Martin said Meta Platforms Inc's (NASDAQ: META) falling brand value is a lead indicator for rising customer acquisition costs, churn levels, and declining pricing power.

Here's Why Needham Sees Apple's Brand Value Worth At $1T

Needham analyst Laura Martin believes lifetime value (LTV) is the primary driver of upside value for Apple Inc (NASDAQ: AAPL) and that brand value is a leading indicator of LTV in a note titled "AAPL's Brand is Worth $1 Trillion."

Needham Lists Its Top Picks After Attending Fiber Connect 2022 Conference

Needham Lists Its Top Picks After Attending Fiber Connect 2022 Conference

Needham analysts Ryan Koontz and Chad Tevebaugh attended the Fiber Connect 2022 conference in Nashville. They heard from U.S. operators and met with many public and private companies in the broadband access space.

Get all your
news in one place.

100's of premium titles.
One news app.

A Look At Needham's Top FinTech Picks

After another earnings season and coming off the 17th Annual NTMC, Needham analyst Mayank Tandon received updates from its entire coverage universe in recent weeks.

Petco Eyes Small Towns & Rural Communities - Check Out The New Location

Petco Health And Wellness Company Inc (NASDAQ:WOOF) has launched a new community-driven test concept to serve the wellness needs of pets and farm animals in small towns and rural communities. The company will open its first location under the concept on June 17 in Floresville, Texas. Related: Here's Why Needham Is Bullish On This Pet…

Read What Needham Thinks About Blink Charging's SemaConnect Deal

Needham analyst Vikram Bagri raised the price target for Blink Charging Co (NASDAQ:BLNK) to $27 (an upside of 78%) from $25 while maintaining the Buy rating on the shares after the company acquired SemaConnect. The analyst sees eligibility for NEVI funding from newfound eligibility under the Buy America requirement as the biggest near-term deal benefits,…

Needham Sees Reasonable Forecasts For Haemonetics, With Some Tailwinds

Haemonetics Corporation's (NYSE: HAE) analyst day later this month may include an update on its businesses, new products, margin outlook, and financial targets for FY24-FY26.

Get all your
news in one place.

100's of premium titles.
One news app.

Needham Maintains Buy Rating for Pacira BioSciences: Here's What You Need To Know

Needham has decided to maintain its Buy rating of Pacira BioSciences (NASDAQ:PCRX) and lower its price target from $84.00 to $76.00. Shares of Pacira BioSciences are trading up 3.85% over the last 24 hours, at $53.47 per share.

Needham Sees Dynamics Favoring Datadog

Needham analyst Mike Cikos spoke to Datadog, Inc (NASDAQ: DDOG) to recap the ability to sustain growth in a challenging economy and a deeper dive into the consumption elements of Datadog's revenue model.

Here's How Analysts View Braze Post Q1 Beat

Analysts acknowledged Braze, Inc's (NASDAQ:BRZE) Q1 beat amid macro headwinds. Piper Sandler analyst Brent Bracelin maintained Braze with an Overweight and cut the price target from $65 to $42 based on lower growth assumptions given increasing external risks. Despite increasing macro headwinds, BRZE delivered another strong quarter. Increasing investments in direct-to-consumer (DTC) and first-party data stacks have…

Read Needham's Views On Braze, EPAM, MongoDB

Needham offered its take on three software & services companies.

Analysts Consider CRISPR Therapeutics' Blood Disorder Trial Data Encouraging, Impressive

CRISPR Therapeutics (NASDAQ: CRSP) presented results from its ongoing Phase 1 COBALT-LYM CTX130 (exa-cel) trial, an allogeneic CAR-T cell therapy targeting CD70 for solid tumors and certain hematologic malignancies.

Here's What It Will Take For Netflix To Win Streaming War

Analysts grow cautious regarding Netflix, Inc (NASDAQ:NFLX) over brewing competition in the post-Covid world. Needham analyst Laura Martin saw Netflix as unlikely to win the Streaming Wars pending launch of a lower-priced ad-driven tier, adding Sports and News content, bundling with other products, and acquiring an extensive film and TV content library. Every major streaming competitor does one or…

Needham Recommends Every Portfolio Should Stock Up On Innovid - Read Why

Needham analyst Laura Martin re-rated Innovid Corp (NYSE: CTV), justifying why every portfolio should contain the shares.

1 … 11 12 13 14

People

Bernie McTernan

Patrick Walravens

From analysis to the latest developments in health,
read the most diverse news in one place.

inkl

Organisations

Amazon.com Inc.

Wikimedia Commons

inkl

Read news from The Economist, FT, and more,
with one subscription

Topics

Places

367,743 stories

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.

Download on the AppStore

Get it on Google Play